Molecular Mechanism, Biomarkers and Prevention Strategies of Drug-Induced Nephrotoxicity

Overview of Kidney Physiology and Its Susceptibility to Drug Toxicity

The kidneys are highly specialised organs responsible for maintaining systemic homeostasis through regulation of fluid balance, electrolyte composition, acid–base equilibrium, and elimination of metabolic waste products and xenobiotics. Each kidney contains approximately one million nephrons, which function as the structural and functional units responsible for filtration, reabsorption, secretion, and excretion processes. Renal blood flow accounts for nearly 20–25% of total cardiac output, exposing renal tissues to high concentrations of circulating drugs and their metabolites [1]. This extensive exposure is compounded by the presence of specialised transport systems such as organic anion transporters (OATs), organic cation transporters (OCTs), and P-glycoprotein, which actively facilitate drug uptake into tubular epithelial cells. While these transporters are essential for drug clearance, they also contribute to intracellular accumulation of nephrotoxic compounds, thereby increasing susceptibility to cellular injury. The proximal tubule is particularly vulnerable due to its high metabolic activity and abundance of mitochondria, which are required to sustain active transport mechanisms. These cells depend heavily on oxidative phosphorylation, making them highly sensitive to mitochondrial dysfunction and oxidative stress. Furthermore, the renal medulla operates under relatively hypoxic conditions compared to the cortex, rendering it more susceptible to ischemic injury when exposed to nephrotoxic agents. Drugs that alter renal hemodynamics, impair mitochondrial function, or induce oxidative stress can disrupt these finely balanced processes, leading to structural and functional damage. Additionally, the kidney’s role in concentrating urine can result in higher intratubular drug concentrations, further exacerbating toxicity. These physiological characteristics collectively explain why the kidney is one of the primary targets of drug-induced toxicity [2].

Importance of Studying Drug-Induced Nephrotoxicity

Drug-induced nephrotoxicity (DIN) is a critical concern in modern clinical practice due to its high prevalence and potential to cause severe and sometimes irreversible renal damage. With the increasing use of complex pharmacotherapy, particularly in elderly and critically ill populations, the risk of nephrotoxicity has risen substantially. Understanding the mechanisms underlying DIN is essential for optimising drug safety, improving therapeutic outcomes, and minimising adverse effects. Early identification of nephrotoxic effects enables clinicians to modify or discontinue offending agents before significant renal damage occurs. Research into DIN also plays a vital role in drug development and regulatory science. Preclinical and clinical studies aimed at identifying nephrotoxic potential can guide safer drug design and reduce the likelihood of adverse renal outcomes. Moreover, advances in molecular biology have provided deeper insights into cellular and subcellular mechanisms of kidney injury, including oxidative stress, apoptosis, and inflammatory pathways. These insights have paved the way for the development of targeted therapies and nephroprotective agents. Additionally, the integration of pharmacogenomics into clinical practice offers the potential to identify individuals at higher risk of nephrotoxicity based on genetic predisposition. This personalised approach to medicine is expected to significantly reduce adverse drug reactions. Therefore, studying DIN is not only important for patient care but also for advancing the field of precision medicine [3].

Clinical Burden of Kidney Injury Caused by Drugs

Drug-induced kidney injury represents a substantial clinical and economic burden worldwide. It is estimated that approximately 20% of acute kidney injury (AKI) cases in hospitalised patients are attributable to drug exposure [4]. In intensive care units, the incidence may be even higher due to polypharmacy and the use of high-risk medications. The clinical consequences of DIN range from mild, reversible renal impairment to severe kidney failure requiring renal replacement therapy such as dialysis. These outcomes are associated with increased morbidity, mortality, and prolonged hospital stays. The burden of DIN is particularly significant in vulnerable populations, including elderly patients, individuals with pre-existing kidney disease, and those with comorbid conditions such as diabetes and hypertension. In oncology, nephrotoxic chemotherapeutic agents like cisplatin are widely used, further contributing to the prevalence of renal injury. Similarly, in infectious disease management, antibiotics such as aminoglycosides and vancomycin are commonly implicated. The economic impact of DIN includes increased healthcare costs due to extended hospitalisation, additional diagnostic testing, and therapeutic interventions. Furthermore, progression to chronic kidney disease (CKD) can result in long-term healthcare expenses and reduced quality of life. These factors highlight the urgent need for improved prevention, early detection, and management strategies to mitigate the burden of drug-induced nephrotoxicity [5].

2. Epidemiology and Clinical Significance of Drug-Induced Nephrotoxicity

Prevalence of Nephrotoxicity in Hospitalised Patients

The prevalence of drug-induced nephrotoxicity in hospitalised patients varies widely depending on the clinical setting, patient demographics, and types of medications used. Studies have reported that approximately 10–25% of hospitalised patients experience some degree of drug-related renal impairment [6]. In critically ill patients admitted to intensive care units, the incidence is significantly higher due to the combined effects of severe illness, hemodynamic instability, and exposure to multiple nephrotoxic agents. The widespread use of contrast media, antibiotics, and chemotherapeutic drugs further contributes to this high prevalence. Despite its frequency, drug-induced nephrotoxicity is often underdiagnosed or recognised late in its course. This is largely due to the limitations of conventional biomarkers such as serum creatinine, which may not reflect early kidney injury. Additionally, symptoms of nephrotoxicity are often nonspecific, making clinical diagnosis challenging. Epidemiological studies have emphasised the importance of early detection and monitoring strategies to reduce the incidence and severity of renal injury. Improved awareness among healthcare professionals and the implementation of risk assessment protocols can significantly decrease the burden of nephrotoxicity. Furthermore, population-based studies have highlighted disparities in incidence rates across different regions, reflecting variations in healthcare practices and access to diagnostic tools. Understanding these epidemiological patterns is essential for developing effective prevention and management strategies [7].

Major Classes of Nephrotoxic Drugs

A wide range of therapeutic agents have been implicated in drug-induced nephrotoxicity, each with distinct mechanisms of action and patterns of renal injury. Aminoglycoside antibiotics, such as gentamicin, are well-known for their nephrotoxic potential. These drugs accumulate in proximal tubular cells through receptor-mediated endocytosis, leading to lysosomal dysfunction, oxidative stress, and eventual cell death [8]. Vancomycin, another commonly used antibiotic, has been associated with dose-dependent nephrotoxicity, particularly when used in combination with other nephrotoxic agents such as piperacillin–tazobactam. Cisplatin, a widely used chemotherapeutic agent, is one of the most potent nephrotoxins in clinical practice. It induces renal injury through multiple mechanisms, including oxidative stress, inflammation, and DNA damage. Non-steroidal anti-inflammatory drugs (NSAIDs) exert their nephrotoxic effects by inhibiting cyclooxygenase enzymes, leading to reduced prostaglandin synthesis and decreased renal blood flow [11]. Radiographic contrast agents are another major cause of nephrotoxicity, particularly in patients with pre-existing kidney disease. These agents cause vasoconstriction, oxidative stress, and direct tubular toxicity, resulting in contrast-induced nephropathy [12]. Calcineurin inhibitors such as cyclosporine and tacrolimus are widely used in transplant medicine but are associated with chronic nephrotoxicity characterized by vasoconstriction, fibrosis, and progressive decline in renal function. Other anticancer agents, including methotrexate and ifosfamide, also contribute to renal injury through crystal formation and tubular toxicity. The diversity of these drug classes underscores the complexity of nephrotoxicity and highlights the need for individualized risk assessment and management strategies [13,14].

Risk Factors and Susceptible Populations

The development of drug-induced nephrotoxicity is influenced by a complex interplay of patient-related and drug-related factors. Patient-related factors include advanced age, pre-existing kidney disease, diabetes mellitus, hypertension, and dehydration [15]. Elderly patients are particularly vulnerable due to age-related decline in renal function and increased likelihood of polypharmacy. Drug-related factors such as high dosage, prolonged duration of therapy, and concurrent use of multiple nephrotoxic agents significantly increase the risk of renal injury.

High-risk populations include critically ill patients, transplant recipients, and individuals undergoing chemotherapy. Genetic predisposition also plays a role, with certain polymorphisms affecting drug metabolism and transport. Environmental factors such as inadequate hydration and exposure to nephrotoxic substances further contribute to susceptibility. Understanding these risk factors is essential for identifying at-risk individuals and implementing preventive strategies. Risk stratification models and clinical decision support systems can aid in minimizing the incidence of nephrotoxicity in clinical practice [16].

Clinical Consequences and Outcomes

Drug-induced nephrotoxicity can lead to a broad spectrum of clinical outcomes ranging from mild, transient renal impairment to severe and irreversible kidney damage. One of the most common manifestations is acute kidney injury (AKI), characterized by a rapid decline in glomerular filtration rate (GFR), leading to accumulation of nitrogenous waste products such as creatinine and urea in the blood. AKI can develop within hours to days following exposure to nephrotoxic agents and may progress to life-threatening complications if not managed promptly [17]. In many cases, repeated or severe episodes of AKI can evolve into chronic kidney disease (CKD), which is associated with progressive loss of renal function and increased risk of cardiovascular morbidity and mortality. Electrolyte imbalances are another important consequence of nephrotoxicity. Disruption of tubular function can lead to abnormalities such as hyperkalemia, hyponatremia, hypocalcaemia, and metabolic acidosis. These disturbances can have significant clinical implications, including cardiac arrhythmias and neuromuscular dysfunction. Fluid overload is also commonly observed due to impaired renal excretion of sodium and water, leading to edema, pulmonary congestion, and hypertension. In severe cases, patients may require renal replacement therapy such as hemodialysis or peritoneal dialysis to maintain homeostasis. The long-term outcomes of drug-induced nephrotoxicity depend on the severity and duration of injury, as well as the patient’s baseline renal function and comorbid conditions. Early detection and intervention can significantly improve prognosis, while delayed recognition often results in irreversible damage. Additionally, nephrotoxicity may necessitate discontinuation or modification of essential medications, potentially compromising treatment efficacy in conditions such as cancer and severe infections. Therefore, understanding the clinical consequences of nephrotoxicity is essential for optimising patient management and improving outcomes [18].

Economic and Healthcare Burden

Drug-induced nephrotoxicity imposes a substantial economic burden on healthcare systems worldwide. The direct costs associated with nephrotoxicity include prolonged hospitalisation, diagnostic investigations, pharmacological interventions, and renal replacement therapies. Patients who develop AKI often require intensive monitoring and supportive care, significantly increasing healthcare expenditures. Furthermore, the need for dialysis in severe cases adds considerable financial strain onboth patients and healthcare systems [19]. Indirect costs also contribute significantly to the overall burden. These include loss of productivity due to prolonged illness, long-term disability, and reduced quality of life. Patients who progress to chronic kidney disease require ongoing medical care, including regular monitoring, medication, and potential kidney transplantation. The economic impact is particularly pronounced in low- and middle-income countries, where access to healthcare resources may be limited. In addition to financial costs, nephrotoxicity also affects healthcare resource utilisation. Increased demand for hospital beds, dialysis units, and specialised care services places significant pressure on healthcare infrastructure. Preventive strategies, including early detection and risk management, can help reduce these burdens. Cost-effective approaches such as therapeutic drug monitoring and patient education have been shown to improve outcomes and reduce healthcare expenditures. Therefore, addressing drug-induced nephrotoxicity is not only a clinical priority but also an economic necessity [20].

Clinical Significance and Need for Early Detection

The clinical significance of drug-induced nephrotoxicity lies in its potential to cause irreversible kidney damage if not detected early. Traditional diagnostic methods rely heavily on serum creatinine levels, which are often insensitive and may not reflect early renal injury. By the time creatinine levels rise, significant nephron damage may have already occurred [21]. This delay in detection limits the effectiveness of therapeutic interventions and increases the risk of adverse outcomes. Early detection of nephrotoxicity allows for timely modification or discontinuation of the offending drug, thereby preventing further damage. Advances in biomarker research have led to the identification of novel indicators such as KIM-1, NGAL, and cystatin C, which can detect kidney injury at an earlier stage. Incorporating these biomarkers into clinical practice can significantly improve diagnostic accuracy and patient outcomes. Moreover, early detection is particularly important in high-risk populations, including critically ill patients and those receiving nephrotoxic chemotherapy. Regular monitoring and risk assessment can help identify early signs of renal impairment and guide appropriate interventions. The integration of electronic health records and clinical decision support systems has further enhanced the ability to detect and manage nephrotoxicity. Therefore, improving early detection strategies is essential for reducing the burden of drug-induced kidney injury [21].

4. Classification of Drug-Induced Nephrotoxicity

Drug-induced nephrotoxicity can be classified based on the site and mechanism of injury, which provides a useful framework for diagnosis and management. Acute kidney injury (AKI) is the most common form and is characterized by a sudden decline in renal function, often associated with reduced urine output and elevated serum creatinine levels. AKI may result from direct tubular toxicity, hemodynamic alterations, or obstruction within the renal tubules [22]. Tubular toxicity primarily affects the proximal tubular epithelial cells, which are highly susceptible to drug-induced damage due to their active role in reabsorption and secretion. This type of injury is commonly observed with aminoglycosides and cisplatin. Glomerular injury, on the other hand, involves damage to the glomerular filtration barrier, leading to proteinuria and impaired filtration. Drugs such as non-steroidal anti-inflammatory agents and certain biologics have been implicated in glomerular injury.

Interstitial nephritis is an immune-mediated form of nephrotoxicity characterized by inflammation of the renal interstitium. It is often associated with hypersensitivity reactions to drugs such as antibiotics and proton pump inhibitors. Chronic kidney disease related to drugs develops following prolonged or repeated exposure to nephrotoxic agents and is characterized by progressive fibrosis and loss of renal function. Understanding these classifications helps clinicians identify the underlying mechanism of injury and tailor appropriate treatment strategies [23].

5. Pathophysiology of Drug-Induced Kidney Injury

The pathophysiology of drug-induced nephrotoxicity involves complex interactions between pharmacokinetic properties of drugs and renal physiology. One of the key mechanisms is renal drug accumulation, which occurs due to high renal blood flow and active transport processes. Drugs are filtered through the glomerulus and subsequently taken up by tubular cells via transporters such as OATs and OCTs. This leads to intracellular accumulation and potential toxicity [24]. Another important mechanism is alteration of renal hemodynamics. Certain drugs, such as NSAIDs and ACE inhibitors, affect the balance of vasodilatory and vasoconstrictive factors within the kidney, leading to reduced renal perfusion and glomerular filtration rate. This hemodynamic imbalance can result in ischemic injury and exacerbate the effects of other nephrotoxic mechanisms. In addition to these mechanisms, drugs may induce oxidative stress, inflammation, and apoptosis, contributing to cellular injury and dysfunction. The interplay between these pathways determines the severity and progression of nephrotoxicity. Understanding the pathophysiology of drug-induced kidney injury is essential for developing targeted therapeutic interventions and preventive strategies [25].

6. Molecular Mechanisms of Drug-Induced Nephrotoxicity

Drug-induced nephrotoxicity is mediated through a complex network of molecular and cellular mechanisms that ultimately result in structural and functional damage to renal tissues. These mechanisms are often interconnected and may act synergistically to amplify kidney injury. The proximal tubular epithelial cells are particularly vulnerable due to their high metabolic activity, abundance of mitochondria, and exposure to high concentrations of drugs and their metabolites. At the molecular level, nephrotoxicity is primarily driven by oxidative stress, mitochondrial dysfunction, activation of apoptotic and necrotic pathways, inflammatory signaling cascades, endoplasmic reticulum (ER) stress, and dysregulation of autophagy. These processes disrupt cellular homeostasis, impair energy metabolism, and lead to cell death. Understanding these molecular mechanisms is crucial for identifying therapeutic targets and developing effective prevention strategies. Furthermore, the interplay between genetic susceptibility and environmental factors can modulate these pathways, influencing the severity and progression of renal injury. Advances in molecular biology have provided significant insights into these mechanisms, paving the way for novel interventions aimed at mitigating drug-induced kidney damage [24,25].

Oxidative Stress and Reactive Oxygen Species (ROS)

Oxidative stress is one of the most critical and widely recognised mechanisms underlying drug-induced nephrotoxicity. It occurs when there is an imbalance between the generation of reactive oxygen species (ROS) and the antioxidant defence systems of the cell. Nephrotoxic drugs such as cisplatin, aminoglycosides, and radiocontrast agents significantly increase ROS production within renal tubular cells. These reactive species, including superoxide anions, hydrogen peroxide, and hydroxyl radicals, can cause extensive damage to cellular components such as lipids, proteins, and DNA [26]. Lipid peroxidation of cell membranes leads to loss of membrane integrity and increased permeability, while protein oxidation affects enzyme activity and structural proteins. DNA damage can result in mutations and activation of cell death pathways. In addition to direct damage, ROS also act as signalling molecules that activate various intracellular pathways, including nuclear factor-kappa B (NF-κB) and mitogen-activated protein kinases (MAPKs), which promote inflammation and apoptosis. The depletion of endogenous antioxidants such as glutathione, superoxide dismutase, and catalase further exacerbates oxidative stress. In the kidney, the proximal tubular cells are particularly susceptible due to their high metabolic rate and reliance on oxidative phosphorylation. Persistent oxidative stress can lead to mitochondrial dysfunction, further increasing ROS production in a vicious cycle. Moreover, oxidative stress has been shown to impair renal blood flow by affecting endothelial function, thereby contributing to ischemic injury. Therapeutic strategies aimed at enhancing antioxidant defences have shown promise in reducing nephrotoxicity, highlighting the central role of oxidative stress in the pathogenesis of drug-induced kidney injury [26].

Mitochondrial Dysfunction

Mitochondrial dysfunction plays a pivotal role in the development of drug-induced nephrotoxicity due to the high energy demands of renal tubular cells. Mitochondria are responsible for ATP production through oxidative phosphorylation, which is essential for maintaining cellular functions such as active transport and ion balance. Nephrotoxic drugs can disrupt mitochondrial integrity and function by damaging the electron transport chain, leading to decreased ATP production and increased generation of ROS [27].

Structural alterations in mitochondria, such as swelling, loss of cristae, and membrane depolarization, are commonly observed in nephrotoxic conditions. These changes compromise mitochondrial permeability and lead to the release of pro-apoptotic factors such as cytochrome c into the cytosol. The release of these factors triggers the intrinsic apoptotic pathway, resulting in programmed cell death. Additionally, mitochondrial DNA is highly susceptible to oxidative damage due to its proximity to the electron transport chain and lack of protective histones. Damage to mitochondrial DNA further impairs energy production and exacerbates cellular injury. Mitochondrial dysfunction also disrupts calcium homeostasis, leading to intracellular calcium overload, which can activate various degradative enzymes and contribute to cell death. The interplay between oxidative stress and mitochondrial dysfunction creates a feedback loop that amplifies renal injury. Therapeutic approaches targeting mitochondrial protection, such as the use of mitochondrial antioxidants and agents that stabilize mitochondrial membranes, have shown potential in reducing nephrotoxicity. Therefore, preserving mitochondrial function is a key strategy in preventing drug-induced kidney injury [27].

Apoptosis and Necrosis Pathways

Apoptosis and necrosis are two important forms of cell death involved in drug-induced nephrotoxicity, and their relative contribution depends on the severity and duration of injury. Apoptosis is a regulated, energy-dependent process characterised by cell shrinkage, chromatin condensation, and DNA fragmentation.It is primarily mediated through intrinsic (mitochondrial) and extrinsic (death receptor) pathways. In nephrotoxicity, mitochondrial damage leads to the release of cytochrome c, which activates caspase enzymes and initiates the apoptotic cascade [28]. Necrosis, on the other hand, is an uncontrolled form of cell death resulting from severe cellular injury. It is characterised by cell swelling, membrane rupture, and release of intracellular contents, which can trigger inflammation. In the context of drug-induced nephrotoxicity, high concentrations of toxic agents or prolonged exposure can overwhelm cellular repair mechanisms, leading to necrosis. The coexistence of apoptosis and necrosis in renal tissues contributes to both structural damage and inflammatory responses. Recent studies have also identified other forms of regulated cell death, such as necroptosis and ferroptosis, which play a role in nephrotoxicity. Ferroptosis, in particular, is characterised by iron-dependent lipid peroxidation and has been implicated in cisplatin-induced kidney injury. The balance between cell survival and death pathways is critical in determining the outcome of nephrotoxic injury. Targeting these pathways through pharmacological interventions may provide new therapeutic opportunities for preventing renal damage [28].

Inflammation and Cytokine Signalling

Inflammation is a key contributor to the progression of drug-induced nephrotoxicity and is closely linked to oxidative stress and cell death mechanisms. Nephrotoxic drugs can activate immune responses within the kidney, leading to the release of pro-inflammatory cytokines such as tumour necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), and interleukin-1 beta (IL-1β). These cytokines promote the recruitment and activation of immune cells, including neutrophils and macrophages, which further exacerbate tissue injury [29]. Activation of transcription factors such as NF-κB plays a central role in regulating inflammatory gene expression. Once activated, NF-κB translocases to the nucleus and induces the expression of various pro-inflammatory mediators, chemokines, and adhesion molecules. This leads to sustained inflammation and tissue damage. Additionally, inflammation can disrupt endothelial function, leading to reduced renal blood flow and increased vascular permeability. Chronic inflammation contributes to fibrosis and long-term kidney dysfunction. The deposition of extracellular matrix proteins and activation of fibroblasts result in structural remodelling of renal tissues. Anti-inflammatory therapies targeting cytokine signaling pathways have shown potential in reducing nephrotoxicity. Therefore, controlling inflammation is essential for preventing the progression of drug-induced kidney injury [29].

Endoplasmic Reticulum (ER) Stress

Endoplasmic reticulum stress is an important mechanism in drug-induced nephrotoxicity, particularly in conditions where protein folding and processing are disrupted. The ER is responsible for the synthesis and folding of proteins, and any disturbance in its function can lead to accumulation of misfolded proteins, triggering the unfolded protein response (UPR). Nephrotoxic drugs can induce ER stress by disrupting calcium homeostasis and protein folding mechanisms [30]. The UPR initially acts as a protective mechanism to restore normal ER function; however, prolonged or severe stress can lead to activation of apoptotic pathways. Key signaling pathways involved in ER stress include PERK, ATF6, and IRE1, which regulate gene expression and cellular responses. Persistent ER stress results in activation of pro-apoptotic factors such as CHOP (C/EBP homologous protein), leading to cell death. ER stress is closely linked to oxidative stress and inflammation, forming a network of interconnected pathways that contribute to renal injury. Therapeutic strategies aimed at reducing ER stress, such as chemical chaperones and modulators of UPR signaling, have shown promise in experimental models. Therefore, targeting ER stress represents a potential approach for mitigating drug-induced nephrotoxicity [30].

Autophagy and Cell Death Mechanisms

Autophagy is a cellular process that involves the degradation and recycling of damaged organelles and proteins, playing a crucial role in maintaining cellular homeostasis. In the context of drug-induced nephrotoxicity, autophagy can have both protective and detrimental effects depending on the extent and duration of activation. Under mild stress conditions, autophagy helps remove damaged mitochondria and proteins, thereby promoting cell survival [31]. However, excessive or dysregulated autophagy can lead to autophagic cell death, contributing to renal injury. Nephrotoxic drugs such as cisplatin have been shown to modulate autophagy pathways, leading to either protective or harmful outcomes. The balance between autophagy and apoptosis is critical in determining cell fate. Autophagy is regulated by various signaling pathways, including the mammalian target of rapamycin (mTOR) and AMP-activated protein kinase (AMPK). Disruption of these pathways can impair autophagic function and exacerbate kidney injury. Recent studies suggest that modulation of autophagy may provide therapeutic benefits in preventing nephrotoxicity. Therefore, understanding the role of autophagy in kidney injury is essential for developing targeted interventions [31].

7. Conventional Biomarkers for Nephrotoxicity

The assessment of renal function in clinical practice has traditionally relied on a limited set of biochemical markers, primarily serum creatinine and blood urea nitrogen (BUN). These conventional biomarkers have been widely used due to their simplicity, accessibility, and cost-effectiveness. However, despite their routine clinical use, these markers have significant limitations, particularly in the early detection of drug-induced nephrotoxicity. Renal injury often begins at the cellular and molecular levels long before measurable changes in these biomarkers become evident. As a result, reliance on traditional indicators can delay diagnosis and intervention, potentially leading to irreversible kidney damage.

The need for accurate and timely detection of nephrotoxicity has prompted extensive research into alternative biomarkers that can provide earlier and more specific indications of renal injury. Nevertheless, understanding the role, advantages, and limitations of conventional biomarkers remains essential, as they continue to serve as the foundation of clinical assessment. These biomarkers are particularly useful for monitoring disease progression and guiding treatment decisions in established kidney injury. However, their inability to detect subtle or early changes in renal function underscores the importance of integrating them with more sensitive diagnostic tools. In this section, the characteristics and clinical relevance of serum creatinine, blood urea nitrogen, and the limitations of traditional biomarkers [32].

Serum Creatinine

Serum creatinine is the most commonly used biomarker for evaluating renal function and is widely regarded as a standard indicator of glomerular filtration rate (GFR). Creatinine is a metabolic byproduct of creatine phosphate in muscle tissue and is produced at a relatively constant rate under normal physiological conditions. It is freely filtered by the glomerulus and is not significantly reabsorbed, making it a useful marker for assessing kidney function. In clinical practice, increases in serum creatinine levels are indicative of reduced GFR and impaired renal function. Despite its widespread use, serum creatinine has several important limitations that reduce its effectiveness as an early marker of nephrotoxicity. One of the major drawbacks is its delayed response to kidney injury. Significant nephron damage, often exceeding 50%, may occur before a detectable rise in serum creatinine is observed [32]. This delay limits its utility in early diagnosis and timely intervention. Additionally, serum creatinine levels can be influenced by various non-renal factors, including age, gender, muscle mass, diet, and hydration status. For example, individuals with low muscle mass may have deceptively low creatinine levels despite impaired kidney function, while those with high muscle mass may have elevated levels without actual renal dysfunction. Furthermore, serum creatinine does not provide information about the location or mechanism of kidney injury. It is primarily a functional marker and does not reflect structural damage at the cellular level. In the context of drug-induced nephrotoxicity, this limitation is particularly significant, as early injury often occurs at the tubular level before affecting glomerular filtration. Despite these limitations, serum creatinine remains an essential tool for monitoring renal function due to its availability and ease of measurement. It is often used in combination with estimated GFR (eGFR) calculations to provide a more comprehensive assessment of kidney function. However, reliance solely on serum creatinine may result in underestimation of early nephrotoxic effects, highlighting the need for more sensitive biomarkers [32].

Blood Urea Nitrogen (BUN)

Blood urea nitrogen (BUN) is another commonly used biomarker for assessing renal function and is often measured alongside serum creatinine. Urea is a nitrogenous waste product formed in the liver as a result of protein metabolism and is excreted by the kidneys. BUN levels reflect the balance between urea production and excretion, making it an indirect indicator of renal function. Elevated BUN levels are typically associated with reduced kidney function and impaired excretion of urea. However, similar to serum creatinine, BUN has several limitations that restrict its usefulness as a reliable marker of nephrotoxicity. One of the primary limitations is its lack of specificity. BUN levels can be influenced by a variety of non-renal factors, including dietary protein intake, liver function, gastrointestinal bleeding, and hydration status. For instance, high protein intake or increased protein catabolism can lead to elevated BUN levels even in the absence of renal impairment. Conversely, liver disease can result in reduced urea production, leading to lower BUN levels despite kidney dysfunction. In addition, BUN is reabsorbed in the renal tubules, and its levels can be affected by changes in renal blood flow and tubular function. Conditions such as dehydration can increase BUN reabsorption, resulting in elevated levels that may not accurately reflect true renal function. In the context of drug-induced nephrotoxicity, these confounding factors make it difficult to interpret BUN levels accurately. Moreover, BUN is less sensitive than serum creatinine in detecting changes in GFR, particularly in the early stages of kidney injury. It does not provide information about the specific site or mechanism of injury and is therefore limited in its diagnostic utility. Despite these limitations, BUN remains a useful adjunct marker when interpreted in conjunction with serum creatinine and clinical findings. The BUN-to-creatinine ratio is often used to differentiate between prerenal and intrinsic renal causes of kidney dysfunction. However, the overall limitations of BUN highlight the need for more specific and sensitive biomarkers in the diagnosis of drug-induced nephrotoxicity [32].

Limitations of Traditional Biomarkers

Traditional biomarkers such as serum creatinine and BUN, while widely used, have significant limitations that reduce their effectiveness in the early detection and accurate diagnosis of drug-induced nephrotoxicity. One of the most critical limitations is their lack of sensitivity in detecting early renal injury. Both markers typically show significant changes only after substantial loss of kidney function has occurred, which may delay diagnosis and treatment. This delay is particularly problematic in the context of nephrotoxicity, where early intervention is crucial for preventing irreversible damage. Another important limitation is the lack of specificity. Serum creatinine and BUN are influenced by a wide range of non-renal factors, including age, gender, muscle mass, diet, hydration status, and liver function. These variables can lead to misinterpretation of results and reduce the reliability of these markers in clinical practice. Additionally, these biomarkers do not provide information about the underlying cause or location of kidney injury. They are functional markers that reflect changes in GFR but do not indicate structural damage or cellular injury. Furthermore, traditional biomarkers are not capable of distinguishing between different types of kidney injury, such as tubular toxicity, glomerular injury, or interstitial nephritis. This limitation makes it difficult to identify the specific mechanism of nephrotoxicity and tailor appropriate treatment strategies. In addition, these markers are not predictive of long-term outcomes and may not accurately reflect the severity of injury. The growing recognition of these limitations has led to increased interest in the development of novel biomarkers that can provide earlier, more specific, and mechanistically informative insights into kidney injury. Biomarkers such as KIM-1, NGAL, and cystatin C have shown promise in addressing these gaps. However, despite their limitations, traditional biomarkers continue to play an important role in clinical practice due to their accessibility and established use. Integrating these markers with newer diagnostic tools represents a promising approach for improving the detection and management of drug-induced nephrotoxicity [32].